|Bid||36.10 x 800|
|Ask||84.98 x 800|
|Day's range||66.00 - 71.24|
|52-week range||41.41 - 109.00|
|PE ratio (TTM)||N/A|
|Earnings date||31 Jul 2018 - 6 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||104.43|
The updates from ASCO can be practice-changing for doctors, life-changing for patients, and — for investors — market-moving.
It's another win for gene-targeted cancer drugs in lung cancer. The new data sets up a duel between Loxo and another biotechnology firm, Blueprint Medicines, which showed off data from a similar targeted drug in April.
Blueprint Medicines (BPMC) saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 90 to 93. [ibd-display-video id=2385970 width=50 float=left autostart=true] When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.29. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Last Sunday, lots of people were gushing about Blueprint Medicines' experimental cancer drug. The answer: biotech fund managers are paying attention to a scientist who poked holes in Blueprint's data on-stage at the annual meeting of the American Association for Cancer Research, the same venue where Blueprint presented its data. Loxo's shares are up 8% since Blueprint's data were presented.
The Cambridge, Massachusetts-based company said it had a loss of $1.23 per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Biotechnology investors are seeing double Tuesday as two Cambridge, Massachusetts-based firms whose names start with "Blue" head to the equity market to raise cash for promising treatments in ...
Several biotechnology stocks vaulted into double-digit gains after reporting clinical data on blood-disorder medications.